INEOS, the UK's largest private company, and the University of Oxford are launching a new world-leading institute to tackle antimicrobial resistance (AMR). AMR currently causes an estimated 1.5 million excess deaths each year, and could cause over 10 million by 2050.
The new INEOS Oxford Institute will benefit from the internationally outstanding facilities and expertise of the University, which played a vital role in the origin of antibiotics following Fleming and Oxford’s discovery and development of penicillin in the last century. The institute will create collaborative and cross-disciplinary links across the sciences.
The donation by INEOS is one of the largest ever given to a UK university, and builds on the company’s long commitment to philanthropy in the public health space.
The new INEOS Oxford Institute will benefit from the internationally outstanding facilities and expertise of the University, which played a vital role in the origin of antibiotics following Fleming and Oxford’s discovery and development of penicillin in the last century. The institute will create collaborative and cross-disciplinary links across the sciences.
The donation by INEOS is one of the largest ever given to a UK university, and builds on the company’s long commitment to philanthropy in the public health space.
- Category
- Academic
- Tags
- University of Oxford, Oxford, University
Sign in or sign up to post comments.
Be the first to comment